(Q38804821)

English

Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting

scientific article published on 4 May 2017

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

18 June 2018

http://europepmc.org/abstract/PMC/5676955

1 reference

Europe PubMed Central

Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting (English)

1 reference

Europe PubMed Central

PMC publication ID

18 June 2018

http://europepmc.org/abstract/PMC/5676955

1 reference

based on heuristic

inferred from title

3

1 reference

Europe PubMed Central

PMC publication ID

18 June 2018

http://europepmc.org/abstract/PMC/5676955

12

object named as

Nita L Seibel

1 reference

Europe PubMed Central

PMC publication ID

18 June 2018

http://europepmc.org/abstract/PMC/5676955

11

object named as

Wendy B London

1 reference

Europe PubMed Central

PMC publication ID

18 June 2018

http://europepmc.org/abstract/PMC/5676955

10

object named as

Jed G Nuchtern

1 reference

Europe PubMed Central

PMC publication ID

18 June 2018

http://europepmc.org/abstract/PMC/5676955

Katherine K Matthay

18

object named as

Katherine K Matthay

1 reference

Europe PubMed Central

PMC publication ID

18 June 2018

http://europepmc.org/abstract/PMC/5676955

14

object named as

John M Maris

1 reference

Europe PubMed Central

PMC publication ID

18 June 2018

http://europepmc.org/abstract/PMC/5676955

author name string

Julie R Park

1

1 reference

Europe PubMed Central

PMC publication ID

18 June 2018

http://europepmc.org/abstract/PMC/5676955

Rochelle Bagatell

2

1 reference

Europe PubMed Central

PMC publication ID

18 June 2018

http://europepmc.org/abstract/PMC/5676955

Andrew D Pearson

4

1 reference

Europe PubMed Central

PMC publication ID

18 June 2018

http://europepmc.org/abstract/PMC/5676955

Judith G Villablanca

5

1 reference

Europe PubMed Central

PMC publication ID

18 June 2018

http://europepmc.org/abstract/PMC/5676955

Frank Berthold

6

1 reference

Europe PubMed Central

PMC publication ID

18 June 2018

http://europepmc.org/abstract/PMC/5676955

Susan Burchill

7

1 reference

Europe PubMed Central

PMC publication ID

18 June 2018

http://europepmc.org/abstract/PMC/5676955

Ariane Boubaker

8

1 reference

Europe PubMed Central

PMC publication ID

18 June 2018

http://europepmc.org/abstract/PMC/5676955

Kieran McHugh

9

1 reference

Europe PubMed Central

PMC publication ID

18 June 2018

http://europepmc.org/abstract/PMC/5676955

O Wolf Lindwasser

13

1 reference

Europe PubMed Central

PMC publication ID

18 June 2018

http://europepmc.org/abstract/PMC/5676955

Penelope Brock

15

1 reference

Europe PubMed Central

PMC publication ID

18 June 2018

http://europepmc.org/abstract/PMC/5676955

Gudrun Schleiermacher

16

1 reference

Europe PubMed Central

PMC publication ID

18 June 2018

http://europepmc.org/abstract/PMC/5676955

Ruth Ladenstein

17

1 reference

Europe PubMed Central

PMC publication ID

18 June 2018

http://europepmc.org/abstract/PMC/5676955

language of work or name

0 references

publication date

4 May 2017

1 reference

Europe PubMed Central

PMC publication ID

18 June 2018

http://europepmc.org/abstract/PMC/5676955

Journal of Clinical Oncology

1 reference

Europe PubMed Central

PMC publication ID

18 June 2018

http://europepmc.org/abstract/PMC/5676955

35

1 reference

Europe PubMed Central

PMC publication ID

18 June 2018

http://europepmc.org/abstract/PMC/5676955

22

1 reference

Europe PubMed Central

PMC publication ID

18 June 2018

http://europepmc.org/abstract/PMC/5676955

2580-2587

1 reference

Europe PubMed Central

PMC publication ID

18 June 2018

http://europepmc.org/abstract/PMC/5676955

Recommendations for the standardization of bone marrow disease assessment and reporting in children with neuroblastoma on behalf of the International Neuroblastoma Response Criteria Bone Marrow Working Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5676955

22 June 2018

Nuclear Medicine in Pediatric and Adolescent Tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5676955

22 June 2018

Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5676955

22 June 2018

Assessment of Primary Site Response in Children With High-Risk Neuroblastoma: An International Multicenter Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5676955

22 June 2018

124I-MIBG: a new promising positron-emitting radiopharmaceutical for the evaluation of neuroblastoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5676955

22 June 2018

Advances in Risk Classification and Treatment Strategies for Neuroblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5676955

22 June 2018

Clinical Significance of Persistent Tumor in Bone Marrow during Treatment of High-risk Neuroblastoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5676955

22 June 2018

131I-metaiodobenzylguanidine with intensive chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma. A new approaches to neuroblastoma therapy (NANT) phase II study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5676955

22 June 2018

Phase I/II study of (131)I-MIBG with vincristine and 5 days of irinotecan for advanced neuroblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5676955

22 June 2018

Neuroblastoma: paradigm for precision medicine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5676955

22 June 2018

Phase II study of temozolomide in combination with topotecan (TOTEM) in relapsed or refractory neuroblastoma: a European Innovative Therapies for Children with Cancer-SIOP-European Neuroblastoma study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5676955

22 June 2018

Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5676955

22 June 2018

Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: a report from the New Approaches to Neuroblastoma Therapy (NANT) consortium.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5676955

22 June 2018

Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children's oncology group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5676955

22 June 2018

Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: results of Children's Oncology Group study P9641.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5676955

22 June 2018

The significance of serial histopathology in a residual mass for outcome of intermediate risk stage 3 neuroblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5676955

22 June 2018

Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the Children's Oncology Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5676955

22 June 2018

Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5676955

22 June 2018

177Lu-DOTATATE molecular radiotherapy for childhood neuroblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5676955

22 June 2018

Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group Project

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5676955

22 June 2018

Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5676955

22 June 2018

Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children's Oncology Group study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5676955

22 June 2018

Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5676955

22 June 2018

Outcome after reduced chemotherapy for intermediate-risk neuroblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5676955

22 June 2018

Randomized Trial of prophylactic granulocyte colony-stimulating factor during rapid COJEC induction in pediatric patients with high-risk neuroblastoma: the European HR-NBL1/SIOPEN study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5676955

22 June 2018

Criteria for evaluation of disease extent by (123)I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5676955

22 June 2018

Comparison of iodine-123 metaiodobenzylguanidine (MIBG) scan and [18F]fluorodeoxyglucose positron emission tomography to evaluate response after iodine-131 MIBG therapy for relapsed neuroblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5676955

22 June 2018

International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5676955

22 June 2018

Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5676955

22 June 2018

Iodine-131--metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: a new approaches to neuroblastoma therapy phase I study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5676955

22 June 2018

Sensitivity of surveillance studies for detecting asymptomatic and unsuspected relapse of high-risk neuroblastoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5676955

22 June 2018

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5676955

22 June 2018

MIBG scintigraphy for the diagnosis and follow-up of children with neuroblastoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5676955

22 June 2018

The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5676955

22 June 2018

Treatment of localised resectable neuroblastoma. Results of the LNESG1 study by the SIOP Europe Neuroblastoma Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5676955

22 June 2018

High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5676955

22 June 2018

Review of image defined risk factors in localized neuroblastoma patients: Results of the GPOH NB97 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5676955

22 June 2018

RECIST revisited: a review of validation studies on tumour assessment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5676955

22 June 2018

Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5676955

22 June 2018

Micrometastases in neuroblastoma: are they clinically important?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5676955

22 June 2018

Detection of disseminated tumor cells in neuroblastoma: 3 log improvement in sensitivity by automatic immunofluorescence plus FISH (AIPF) analysis compared with classical bone marrow cytology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5676955

22 June 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5676955

22 June 2018

Nuclear medicine imaging of pheochromocytoma and neuroblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5676955

22 June 2018

Metastatic neuroblastoma in children older than one year: prognostic significance of the initial metaiodobenzylguanidine scan and proposal for a scoring system

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5676955

22 June 2018

Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5676955

22 June 2018

A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk Neuroblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5676955

31 August 2018

Minimal residual disease detection in autologous stem cell grafts from patients with high risk neuroblastoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5676955

31 August 2018

Neuroblastoma mRNAs predict outcome in children with stage 4 neuroblastoma: a European HR-NBL1/SIOPEN study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5676955

31 August 2018

Iodine-123 metaiodobenzylguanidine scintigraphy scoring allows prediction of outcome in patients with stage 4 neuroblastoma: results of the Cologne interscore comparison study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5676955

31 August 2018

Methylated RASSF1a is the first specific DNA marker for minimal residual disease testing in neuroblastoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5676955

31 August 2018

Comparison of 18F-dopa PET/CT and 123I-MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5676955

31 August 2018

¹²³I-MIBG scintigraphy/SPECT versus ¹⁸F-FDG PET in paediatric neuroblastoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5676955

31 August 2018

18F-FDG PET/CT and 123I-metaiodobenzylguanidine imaging in high-risk neuroblastoma: diagnostic comparison and survival analysis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5676955

31 August 2018

123I-MIBG scintigraphy and 18F-FDG PET in neuroblastoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5676955

31 August 2018

Excellent outcome with reduced treatment for infants with disseminated neuroblastoma without MYCN gene amplification

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5676955

31 August 2018

Evaluation of lymph nodes with RECIST 1.1.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5676955

31 August 2018

The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5676955

31 August 2018

The prognostic impact of functional imaging with (123)I-mIBG in patients with stage 4 neuroblastoma >1 year of age on a high-risk treatment protocol: results of the German Neuroblastoma Trial NB97.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5676955

31 August 2018

Early Molecular Response of Marrow Disease to Biologic Therapy Is Highly Prognostic in Neuroblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5676955

31 August 2018

Correlation of early metastatic response by 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5676955

31 August 2018

Impact of metaiodobenzylguanidine scintigraphy on assessing response of high-risk neuroblastoma to dose-intensive induction chemotherapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5676955

31 August 2018

Patterns of relapse after autologous purged bone marrow transplantation for neuroblastoma: a Childrens Cancer Group pilot study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5676955

31 August 2018

Minimal residual disease is a prognostic marker for neuroblastoma with bone marrow infiltration

1 reference

https://pubmed.ncbi.nlm.nih.gov/28471719

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Plasma glucose and insulin, urinary catecholamine and cortisol responses to test breakfasts with high or low fibre content: the importance of the previous diet

1 reference

https://pubmed.ncbi.nlm.nih.gov/28471719

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Current concepts on the diagnostic use of MIBG in children

1 reference

https://pubmed.ncbi.nlm.nih.gov/28471719

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment and outcomes of patients with relapsed, high-risk neuroblastoma: results of German trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/28471719

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A new 123I-MIBG whole body scan scoring method--application to the prediction of the response of metastases to induction chemotherapy in stage IV neuroblastoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/28471719

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of diet on urinary excretion of VMA, HVA, metanephrine, and total free catecholamine in normal preschool children

1 reference

https://pubmed.ncbi.nlm.nih.gov/28471719

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Detection of metastatic neuroblastoma in bone marrow: when is routine marrow histology insensitive?

1 reference

https://pubmed.ncbi.nlm.nih.gov/28471719

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2016.72.0177

1 reference

Europe PubMed Central

PMC publication ID

18 June 2018

http://europepmc.org/abstract/PMC/5676955

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

18 June 2018

http://europepmc.org/abstract/PMC/5676955

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

18 June 2018

http://europepmc.org/abstract/PMC/5676955

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38804821&oldid=2186461490"